Načítá se...
Development of encorafenib for BRAF-mutated advanced melanoma
PURPOSE OF REVIEW: To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with established BRAF-inhibitors in the treatment of locally advanced or metastatic melan...
Uloženo v:
| Vydáno v: | Curr Opin Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5815646/ https://ncbi.nlm.nih.gov/pubmed/29356698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0000000000000426 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|